CA3227139A1 - Methods for inhibiting the progression of oxidative retinal diseases - Google Patents
Methods for inhibiting the progression of oxidative retinal diseases Download PDFInfo
- Publication number
- CA3227139A1 CA3227139A1 CA3227139A CA3227139A CA3227139A1 CA 3227139 A1 CA3227139 A1 CA 3227139A1 CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A1 CA3227139 A1 CA 3227139A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- patient
- progression
- ester
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3311344A CA3311344A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224679P | 2021-07-22 | 2021-07-22 | |
| US202163224690P | 2021-07-22 | 2021-07-22 | |
| US202163224674P | 2021-07-22 | 2021-07-22 | |
| US63/224,690 | 2021-07-22 | ||
| US63/224,674 | 2021-07-22 | ||
| US63/224,679 | 2021-07-22 | ||
| PCT/US2022/038072 WO2023004151A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3311344A Division CA3311344A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227139A1 true CA3227139A1 (en) | 2023-01-26 |
Family
ID=84979648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227139A Pending CA3227139A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
| CA3311344A Pending CA3311344A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3311344A Pending CA3311344A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250099415A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4373479A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024526939A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240036651A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022313207A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3227139A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310210A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023004151A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240091187A1 (en) * | 2022-09-02 | 2024-03-21 | Biojiva Llc | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270739A1 (en) * | 2005-04-28 | 2006-11-30 | Trustees Of Tufts College | Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation |
| US20100303887A1 (en) * | 2007-07-30 | 2010-12-02 | Bazan Nicolas G | DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells |
| EP2219638A2 (en) * | 2007-10-29 | 2010-08-25 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Lipoxin a4 protection for retinal cells |
| US10058522B2 (en) * | 2011-04-26 | 2018-08-28 | Retrotope, Inc. | Oxidative retinal diseases |
| WO2017091279A1 (en) * | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| WO2020102596A1 (en) * | 2018-11-15 | 2020-05-22 | Retrotope, Inc. | Deuterated compounds, compositions, and uses |
-
2022
- 2022-07-22 EP EP22846695.9A patent/EP4373479A4/en active Pending
- 2022-07-22 CA CA3227139A patent/CA3227139A1/en active Pending
- 2022-07-22 KR KR1020247005941A patent/KR20240036651A/ko active Pending
- 2022-07-22 IL IL310210A patent/IL310210A/en unknown
- 2022-07-22 WO PCT/US2022/038072 patent/WO2023004151A1/en not_active Ceased
- 2022-07-22 AU AU2022313207A patent/AU2022313207A1/en active Pending
- 2022-07-22 CA CA3311344A patent/CA3311344A1/en active Pending
- 2022-07-22 JP JP2024503840A patent/JP2024526939A/ja active Pending
- 2022-07-22 US US18/291,016 patent/US20250099415A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240036651A (ko) | 2024-03-20 |
| IL310210A (en) | 2024-03-01 |
| CA3311344A1 (en) | 2026-06-21 |
| AU2022313207A1 (en) | 2024-02-29 |
| US20250099415A1 (en) | 2025-03-27 |
| WO2023004151A1 (en) | 2023-01-26 |
| JP2024526939A (ja) | 2024-07-19 |
| EP4373479A1 (en) | 2024-05-29 |
| EP4373479A4 (en) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3735963B1 (en) | Self-emulsifying composition of omega-3 fatty acid | |
| US6417233B1 (en) | Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same | |
| EP3023099B1 (en) | Self-emulsifying composition of -3 fatty acid | |
| US5834032A (en) | Compositions and methods for treating diabetes | |
| EP3248599A1 (en) | Omega-3 fatty acid self-emulsifying composition | |
| UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
| US11351143B1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| WO2003072111A2 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
| EP1689413A2 (en) | Glycerophospholipids containing omega-3 and omega-6 fatty acids | |
| CA3210773A1 (en) | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof | |
| EP3986418A1 (en) | Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy | |
| US20220249422A1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| AU2006324155A1 (en) | Intravenous essential fatty acid emulsion | |
| WO2023004151A1 (en) | Methods for inhibiting the progression of oxidative retinal diseases | |
| KR20180010181A (ko) | Apo c3 의 저하를 위한 티아 옥소 화합물의 용도 | |
| CN118019529A (zh) | 抑制氧化性视网膜疾病进展的方法 | |
| US20240091187A1 (en) | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof | |
| JP2025507361A (ja) | 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法 | |
| JPS6011422A (ja) | 抗筋ジストロフイ−症剤 | |
| KR20260010331A (ko) | L-세린의 리포좀 제형 및 이의 제조 방법 | |
| JP2025506208A (ja) | Als治療のための相乗的併用療法 | |
| JPH05139966A (ja) | 月経困難症予防または治療剤と月経困難症予防機能性食品 | |
| JPS6011421A (ja) | 血中脂質降下剤 | |
| EA046793B1 (ru) | Применение композиции (варианты) для профилактического или терапевтического лечения кальцификации сосудов | |
| JPS6256133B2 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260109 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260309 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260511 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260708 |